UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017261
Receipt number R000020012
Scientific Title Effect of Tamsulosin for Benign Prostate Hyperplasia patient with persistent symptoms: switch from Silodosin.
Date of disclosure of the study information 2015/04/24
Last modified on 2015/11/25 10:42:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of Tamsulosin for Benign Prostate Hyperplasia patient with persistent symptoms: switch from Silodosin.

Acronym

Effect of Tamsulosin for Benign Prostate Hyperplasia patient with persistent symptoms: switch from Silodosin.

Scientific Title

Effect of Tamsulosin for Benign Prostate Hyperplasia patient with persistent symptoms: switch from Silodosin.

Scientific Title:Acronym

Effect of Tamsulosin for Benign Prostate Hyperplasia patient with persistent symptoms: switch from Silodosin.

Region

Japan


Condition

Condition

Benign prostatic hyperplasia

Classification by specialty

Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine efficacy and safety of switch from Silodosin to 0.2 mg Tamsulosin.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

International Prostate Symptom score

Key secondary outcomes



Base

Study type


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

To examine efficacy and safety of switch from Silodosin to 0.2 mg Tamsulosin. (12weeks)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

1. male patients aged 50 or older
2. patients treated with Silodosin 8mg for over 8 weeks
3. question number 3 of QOL score: 3 points or more
4. patients with lower urinary tract symptoms (IPSS: 8 points or more, QOL score 3 points or more)
5. patients who want to change from Silodosin to Tamsulosin
6. patients with informed consent

Key exclusion criteria

1. patients treated with other alpha 1 blocker
2. patients Tamsulosin is contraindicated
3. patients treated with anti cholonergic agents
4. patients treated with anti androgen agents
5. patients treated with drug could change urination
6. patients with prostate cancer
7. patients with the history of TUR-P
8. patients with the history of hyperthermia for benign prostatic hyperplasia
9. patients with neurogenic bladder
10. patients with urethral stricture
11. patients with using self catheterization
12. patients with the history of radiation therapy
13. patients with active urinary infection
14. patients who have been determined to be unsuitable as a subject by a physician

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takahiko Mitsui

Organization

Hokkaido University Graduate School of Medicine

Division name

Department of Renal and Genitourinary surgery

Zip code


Address

North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan

TEL

011-706-5966

Email

mitsui68@med.hokudai.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Takahiko Mitsui

Organization

Hokkaido University Graduate School of Medicine

Division name

Department of Renal and Genitourinary surgery

Zip code


Address

North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan

TEL

011-706-5966

Homepage URL


Email

mitsui68@med.hokudai.ac.jp


Sponsor or person

Institute

Hokkaido University

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 04 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 04 Month 16 Day

Date of IRB


Anticipated trial start date

2010 Year 09 Month 03 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 04 Month 23 Day

Last modified on

2015 Year 11 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020012


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name